The potentiality of vanadium in medicinal applications

Future Medicinal Chemistry

Volumn 4, Issue 14, 2012, Pages 1823-1827

  Rehder, Dieter ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 DIPICOLINIC ACID AMIDE; 1,6 DIPICOLINIC ACID; ALLIXIN; ANTIDIABETIC AGENT; DNA; ETHYLMALTOL; INSULIN; PHOSPHATASE; PYRIDINONE; REACTIVE OXYGEN METABOLITE; SALICYLGLYCINE; UNCLASSIFIED DRUG; VANADIC ACID; VANADIUM; VANADIUM DERIVATIVE; VANADOCENE DERIVATIVE; VANADYL DERIVATIVE;

AMEBIASIS; CHAGAS DISEASE; DENGUE; DIABETES MELLITUS; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEOPLASMS; VANADIUM COMPOUNDS;

EID: 84867345087     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.103     Document Type: Review

References (52)

1. Rehder D.Transport, accumulation and physiological effects of vanadium.In: Detoxification of Heavy Metals. Sherameti I, Varma A (Eds).Soil Biol. 30, 205-230(2011).
2. Costa Pessoa J, Tomaz I.Transport of therapeutic vanadium and ruthenium complexes by blood plasma components.Curr. Med. Chem. 17, 3701-3738(2010).
3. McLauchlan CC, Hooker JD, Jones MA et al. Inhibition of acid, alkaline, and tyrosine (PTP1B)phosphatases by novel vanadium complexes.J. Inorg. Biochem.104, 274-281 (2010).
4. Fredrickson JK, Romine MF, Beliaev AS et al. Towards environmental systems biology of Shewanella. Nature Rev. Microbiol. 6, 592-603 (2008).
5. Pombeiro AJL. Vanadium-catalyzed alkane functionalization reactions under mild conditions. ACS Symposium Series 974 (Vanadium) 51-60(2007).
6. Treberg JR, Stacey JE, Driedzic WR. Vanadium accumulation in ascidian coelomic cells is associated with enhanced pentose phosphate pathway capacity but not overall aerobic or anaerobic metabolism. Comp. Biochem. Physiol. B 161, 323-330(2012).
7. Michibata H, Ueki T. Advances in research on the accumulation, redox behavior, and function of vanadium in ascidians. BioMol. Concepts 1, 97-107 (2010).
8. Fay AW, Blank MA, Lee CC et al. Characterization of isolated nitrogenase FeVco. J. Am. Chem. Soc. 132, 12612-12618(2010).
9. Hu Y, Lee CC, Ribbe MW. Extending the carbon chain: hydrocarbon formation catalyzed by vanadium/molybdenum nitrogenases. Science 333, 753-755 (2011).
10. Kyriazis GA, Sounddarapandian MM, Tyrberg B. Sweet taste receptor signaling in beta cells mediates fructose-induced potentiation of glucose-stimulated insulin secretion. Proc. Natl Acad. Sci. USA 109, 2713-2714 (2012).
11. Scully T. Diabetes in numbers. Nature 458, S2-S3 (2012).
12. Lindquist Y, Schneider G, Vihko P. Crystal structure of rat acid phosphatase complexes with the transition state analogs vanadate and molybdate. Eur. J. Biochem. 221, 139-142 (1994). (Pubitemid 24120555)
13. Clark TA, Heyliger CF, Kopilas M et al. A tea/vanadate decoction delivered orally over 14 months to diabetic rats induces long-term glycemic stability without organ toxicity. Metabolism 61, 742-753 (2012).
14. McNeill JH, Yuen VG, Hoveyda HR, Orvig C. Bis(maltolato)oxovanadium(IV)is a potent insulin mimic. J. Med. Chem. 35, 1489-1491 (1992).
15. Levina A, Lay PA. Metal-baseds anti-diabetic drugs: advances and challenges. Dalton Trans. 40, 11675-11686 (2011).
16. Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C. Vanadium treatment of Type 2 diabetes: a viewto the future. J. Inorg. Biochem. 103, 554-558(2009).
17. Hiromura M, Adachi Y, Machida M, Hattori M, Sakurai H. Glucose lowering activity by oral administration of bis(allixinato)oxidovanadium(IV)complex in streptozotocine-induced diabetic mice and gene expression profiling in their skeletal muscles. Metallomics 1, 92-100(2009).
18. Adachi Y, Yoshida J, Kodera Y, Kahto A, Takada J, Sakurai H. Bis(allixinato)oxovanadium(IV)complex is a potent antidiabetic agent: Studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes. J. Med. Chem. 49, 3251-3256 (2006). (Pubitemid 43830522)
19. Rangel M, Amorim MJ, Nunes A et al. Novel 3-hydroxy-4-pyridinonato oxidovanadium(IV)complexes to investigate structure/activity relationships. J. Inorg. Biochem. 103, 496-502 (2009).
20. Sanna D, Buglyó P, Bíró L, Micera G, Garribba E. Coordinating properties of pyrone and pyridinone derivatives, tropolone and catechol towards the VO2+ ion: An experimental and computational approach. Eur. J. Inorg. Chem. 1079-1092 (2012).
21. Rondini EA, Walters DM, Bauer AK. Vanadium pentoxide induces pulmonary inflammation and tumor promotion in a strain-dependent manner. Particle Fibre Toxicol. 7, 1-13 (2010).
22. Sanna D, Bíró L, Buglyó P, Micera G, Garribba E. Transport of the anti-diabetic VO2+ complexes formed by pyrone derivatives in the blood serum. J. Inorg. Biochem. 115, 87-99(2012).
23. Jakusch T, Hollender D, Enyedy EA et al. Biospeciation of various antidiabetic VIVO compounds in serum. Dalton Trans. 13, 2428-2437 (2009).
24. Delgado TC, Tomaz AI, Corriera I et al. Uptake and metabolic effects of insulin mimetic oxovanadium compounds in human erythrocytes. J. Inorg. Biochem. 99, 2328-2339(2005). (Pubitemid 41741829)
25. Vincent JB, Love S. The binding and transport of alternative metals by transferrin. Biochim. Biophys. Acta 1820, 362-378(2012).
26. Sakurai H, Yoshikawa Y, Yasui H. Current state for the development of metallopharmaceutics and anti-diabetic metal complexes. Chem. Soc. Rev. 37, 2383-2392 (2008).
27. Rehder D. Bioinorganic Vanadium Chemistry. John Wiley & Sons, Chichester, UK (2008).
28. Liu T-T, Liu Y-J, Wang Q, Yang X-G, Wang K. Reactive-oxygen-species- mediated Cdc25C degradation results in differential antiproliferative activities of vanadate, tungstate and molybdate in the PC-3 human prostate cancer cell line. J. Biol. Inorg. Chem. 17, 311-320(2012).
29. Kieler J, Gromek A, Nissen NI. Studies on the antineoplastic effect of vanadium salts. Acta Chir. Scand. 343, 154-164 (1965).
30. Köpf-Maier P, Köpf H. Metallocene complexes: organometallic antitumor agents. Drugs Future 11, 297-319(1986). (Pubitemid 16041077)
31. Evangelou AM. Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol. 42, 249-265 (2002). (Pubitemid 34615688)
32. Bishayee A, Waghray A, Patel MA, Chatterjee M. Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence. Cancer Lett. 294, 1-12 (2010).
33. D'Cruz OJ, Uckun FM, Fatih M. Metvan, a novel oxovanadium(IV)complex with broad spectrum anticancer activity. Expert Opin. Investig. Drugs 11, 1829-1836 (2002). (Pubitemid 35469926)
34. Naso LG, Ferrer EG, Butenko N et al. Antioxidant, DNA cleavage, and cellular effects of silibinin and a newoxovanadium(IV)/silibinin complex. J. Biol. Inorg. Chem. 16, 653-668(2011).
35. Fichtner I, Claffey J, Deally A et al. Antitumor activity of vanadocene Y and its selenocyanate derivative in xenografted caki-1 tumors in mice. J. Organomet. Chem. 695, 1175-1181 (2010).
36. Gleeson B, Deally A, Müller-Bunz H, Patil S, Tacke M. Novel achiral aryl-substituted vanadocenes: synthesis and preliminary cytotoxicity studies. Aust. J. Chem. 63, 1514-1520(2010).
37. Deng C, Zhou L. Binding of ansa and non-ansa-titanocene anticancer drugs to DNA: a DFT study. Struct. Chem. 21, 735-744 (2010).
38. Gambio D. Potentiality of vanadium compounds as anti-parasitic agents. Coord. Chem. Rev. 222, 2193-2203 (2011).
39. Maia PIS, Pavan FR, Leite CQ et al. Vanadium complexed with thiosemicarbazones: synthesis, characterization, crystal structures and anti-mycobacterium tuberculosis activity. Polyhedron 28, 398-406 (2009).
40. Ross A, Soares DC, Covelli D et al. Oxovanadium(IV)cyclam and bicyclam complexes: potential CXCR4 receptor antagonists. Inorg. Chem. 49, 1122-1132 (2010).
41. Turner TL, Nguyen VH, McLaughlan CC et al. Inhibitory effects of decavanadate on several enzymes and Leishmania tarentolae in vitro. J. Inorg. Biochem. 108, 96-104 (2012).
42. Noleto GR, Merce AC, Ana LR et al. Effects of a lichen galactomannan and its vanadyl(IV)complex on peritonial macrophages and leishmanicidal activity. Molec. Cell Biochem. 233, 73-83 (2002). (Pubitemid 34746112)
43. Maurya MR, Alam Khan A, Azam A et al. Vanadium complexes having [VIVO]2+ and [VO2]+ cores with binucleating dibasic tetradentate ligands: Synthesis, characterization, catalytic and antiamoebic activities. Dalton Trans. 39, 1345-1360(2010).
44. Maurya MR, Agarwal S, Abid M et al. Synthesis, characterisation, reactivity and in vitro antiamoebic activity of hydrazone based oxovanadium(IV), oxovanadium(V)and μ-bis(oxo)bis{oxovanadium(V)} complexes. Dalton Trans. 7, 937-947 (2006). (Pubitemid 43261722)
45. Bhuiyan MS, Fukunaga K. Cardioprotection by vanadium compounds targeting Akt-mediated signaling. J. Pharmacol Sci. 110, 1-13 (2009).
46. Willsky GR, Chi L-H, Godzala III M et al. Anti-diabetic effects of a series of vanadium dipicolinate complexed in rats with streptozotocine-induced diabetes. Coord. Chem. Rev. 225, 2258-2269(2011).
47. Nilsson J, Degerman E, Haukka M et al. Bis-and tris(pyridyl)amine- oxidovanadium complexes: characteristics and insulin-mimetic potential. Dalton Trans. 38, 7902-7911 (2009).
48. Nilsson J, Shteinman AA, Degerman E et al. Salicylamide and salicylglycine oxidovanadium complexes with insulin-mimetic properties. J. Inorg. Biochem. 105, 1795-1800(2011).
49. Butler A, Eckert H. Vanadium-51 NMR as a probe of vanadium(V)coorination to human apotransferrin. J. Am. Chem. Soc. 111, 2802-2809(1989). (Pubitemid 19106176)
50. Chi Z, Zhu L, Lu X. Comparison of two dinuclear vanadium-catecholate complexes: synthesis, X-ray structure and effects in cancer cells. J. Mol. Struct. 1001, 111-117 (2011).
51. Lewis NA, Liu F, Seymour L et al. Synthesis, characterization, and preliminary in vitro studies of vanadium(IV)complexes with a Schiff base and thiosemicarbazones as mixed ligand. Eur. J. Inorg. Chem. 664-677 (2012).
52. Benítez J, Guggeri L, Tomaz I et al. Design of vanadium mixed-ligand complexed as potential anti-protozoa agents. J. Inorg. Biochem. 103, 609-616 (2009).